

Rhythm Successfully Validates Two Adjunct Biomarkers

- **Successful technical validation of two adjunct biomarkers for ColoSTAT®**
- **Adjunct biomarkers will support the already validated key lead biomarker**
- **Remaining two adjunct biomarkers progressing through final stage of technical validation**

16 September 2020, Melbourne: Rhythm Biosciences Limited (ASX: RHY) is pleased to confirm that the antibodies for the first two of four adjunct biomarkers have been successfully technically validated, stabilised and proven to be reproduceable. The two adjunct biomarkers, along with our key lead biomarker make up the majority of the principal ingredients needed for ColoSTAT®, Rhythm's global, low-cost, simple blood test for the detection of colorectal cancer aimed at the mass market.

The successful technical validation for these two adjunct biomarkers, which will support the already validated key lead biomarker (ASX Announcement 2nd April 2020), represents another step forward for the Company. Rhythm expects the final two individual biomarkers to be technically validated in the near term. Importantly, for eventual commercialisation, the ColoSTAT® test will predominantly use the Company's own version of antibodies, which are intended to be combined in the final ColoSTAT® test kit.

Rhythm CEO, Glenn Gilbert said: "We continue to focus on the development program and technical validation of what we believe to be the final two adjunct biomarkers that will support the ColoSTAT® test kit. We have a very focused team, and all are reinvigorated with the progress we have made over the past 6 months to advance the core technology".

With the authority of the Board.

For further information, please contact:

Glenn Gilbert
Chief Executive Officer
+61 3 8256 2880

Rhythm Biosciences

ACN: 619 459 335
ASX: **RHY**

Issued Capital

201,495,811 Shares
6,650,000 Options

Australian Registered Office

Level 2, 480 Collins Street
Melbourne VIC 3000
www.rhythmbio.com

Directors

Otto Buttula – Chairman of the Board
Trevor John Lockett – Executive Director
Louis James Panaccio – Non-Executive Director
David John White – Non-Executive Director
Eduardo Vom – Non-Executive Director

About Rhythm Biosciences

ASX-listed Rhythm Biosciences is endeavoring to develop and commercialise a screening and diagnostic test for the early detection of colorectal cancer, the third biggest cause of cancer-related deaths globally.

Rhythm's lead product, ColoSTAT[®], is intended to be a simple, affordable, minimally invasive and effective blood test for the early detection of bowel cancer for the global mass market. It is expected to be comparable to, if not better than, the current standard of care, the faecal immunochemical test (FIT), at a lower overall cost to public health administrations. ColoSTAT[®] also provides an alternative for those who choose not to, or are unable to, be assessed using standard screening programs.

ColoSTAT[®] is designed to be equipment agnostic and easily used by laboratories without the need for additional operator training or additional infrastructure.

ColoSTAT[®] has the potential to play an important role in reducing the morbidity and mortality rates and healthcare costs associated with colorectal cancer. Globally, over 850,000 people die from colorectal cancer each year.